174 related articles for article (PubMed ID: 26802053)
1. Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.
Holler A; Zech M; Ghorashian S; Pike R; Hotblack A; Veliça P; Xue SA; Chakraverty R; Morris EC; Stauss HJ
Haematologica; 2016 Apr; 101(4):482-90. PubMed ID: 26802053
[TBL] [Abstract][Full Text] [Related]
2. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease.
Beyersdorf N; Ding X; Hünig T; Kerkau T
Blood; 2009 Nov; 114(20):4575-82. PubMed ID: 19721011
[TBL] [Abstract][Full Text] [Related]
3. The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.
Li M; Sun K; Redelman D; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):739-50. PubMed ID: 20338256
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
5. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
7. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
8. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
[TBL] [Abstract][Full Text] [Related]
9. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
Hartwig UF; Robbers M; Wickenhauser C; Huber C
Blood; 2002 Apr; 99(8):3041-9. PubMed ID: 11929798
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation.
Rettig MP; Ritchey JK; Prior JL; Haug JS; Piwnica-Worms D; DiPersio JF
J Immunol; 2004 Sep; 173(6):3620-30. PubMed ID: 15356106
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
12. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.
Shand JC; Qin H; Nasholm N; Capitini CM; Fry TJ
Biol Blood Marrow Transplant; 2014 Jan; 20(1):26-36. PubMed ID: 24141010
[TBL] [Abstract][Full Text] [Related]
13. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
[TBL] [Abstract][Full Text] [Related]
14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
15. Focusing of the regulatory T-cell repertoire after allogeneic stem cell transplantation indicates protection from graft-
Odak I; Raha S; Schultze-Florey C; Tavil S; Ravens S; Ganser A; Förster R; Prinz I; Koenecke C
Haematologica; 2019 Dec; 104(12):e577-e580. PubMed ID: 31018979
[No Abstract] [Full Text] [Related]
16. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
[TBL] [Abstract][Full Text] [Related]
17. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
Weiss L; Nusair S; Reich S; Sidi H; Slavin S
Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
[TBL] [Abstract][Full Text] [Related]
18. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Boni A; Muranski P; Cassard L; Wrzesinski C; Paulos CM; Palmer DC; Gattinoni L; Hinrichs CS; Chan CC; Rosenberg SA; Restifo NP
Blood; 2008 Dec; 112(12):4746-54. PubMed ID: 18799724
[TBL] [Abstract][Full Text] [Related]
20. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
Caballero-Velázquez T; Sánchez-Abarca LI; Gutierrez-Cosio S; Blanco B; Calderon C; Herrero C; Carrancio S; Serrano C; del Cañizo C; San Miguel JF; Pérez-Simón JA
Haematologica; 2012 Sep; 97(9):1329-37. PubMed ID: 22532520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
